Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Beelitz – page 19

1 845 clinical trials in Beelitz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Beelitz at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Beelitz

Open in trial search

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:A. Menarini International Licensing S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Dyne Therapeutics Inc.

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Beelitz

What the registry says about research in the country

01 Neurological Disorders Research

Innovative clinical trials focusing on Multiple System Atrophy (MSA), evaluating new therapeutic compounds aimed at slowing disease progression and improving patient outcomes.

  • Novel Treatment Development
  • Disease Progression Management
  • Clinical Efficacy Studies

Multiple investigational treatments are being assessed through controlled clinical studies.

02 Movement Disorders Research

Research initiatives targeting Progressive Supranuclear Palsy (PSP), with studies designed to evaluate innovative therapeutic approaches for this rare neurological condition.

  • Disease Modification Strategies
  • Safety Assessment Protocols
  • Long-term Efficacy Evaluation

Comprehensive 52-week studies are underway to assess new treatment options.

03 Parkinson's Disease Studies

Specialized research focusing on GBA1 gene-related Parkinson's Disease, investigating targeted treatments to address motor function and disease progression.

  • Genetic-based Treatments
  • Motor Function Assessment
  • Pharmacodynamic Studies

Advanced clinical trials utilizing standardized rating scales to measure treatment effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.